A notable issue of direct-acting thrombolytics, of which plasmin is the prototype, has been well documented in in vitro and in vivo models, such as the use of catheter-delivered plasmin for treatment of DVT and PAO. This evidence concerns the gene PLG and deep vein thrombosis.